Perrigo (PRGO) is back in focus after reporting a sizeable first quarter loss driven largely by goodwill impairments and restructuring charges, while still reaffirming full year guidance and completing the Dermacosmetics business sale to support debt reduction.

The stock has been volatile, with a 10.98% 1 month share price return, a 19.95% 3 month share price decline, and a 53.24% 1 year total shareholder return loss, suggesting momentum has weakened despite the latest update.

If Perrigo’s recent swings have you reassessing risk, it can help to widen your watchlist with 35 healthcare AI stocks

With Perrigo trading at US$11.72 and screening on some metrics as discounted versus analyst targets and intrinsic estimates, the key question is whether recent impairments and weak returns are already reflected in the price or if the stock still offers a mispriced opportunity.

Most Popular Narrative: 29% Undervalued

At $11.72, Perrigo is sitting well below the most followed narrative fair value of $16.50, which hinges heavily on a recovery play in core self care and infant nutrition.

The aging global population and rising consumer interest in self-care and wellness continue to create longer-term demand tailwinds for Perrigo's OTC and nutrition products, providing stable, defensive revenue streams even in periods of macro uncertainty. Read the complete narrative.

Want to see how a flat revenue outlook still supports a higher fair value? The narrative focuses on margin repair and a richer future earnings multiple. The full breakdown explains how those pieces fit together.

Result: Fair Value of $16.50 (UNDERVALUED)

However, this depends on pressure in infant nutrition easing and cost inflation remaining manageable, since ongoing category softness or margin squeeze could quickly challenge that upside narrative.

Next Steps

Seeing mixed signals on value and risk so far? Take a closer look at the data now, pressure test both sides of the story, and then weigh up the 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

Do not stop with just one stock story; broaden your opportunity set now by lining up fresh ideas that match your risk tolerance and income goals.

• Target dependable cash generators by reviewing companies in the solid balance sheet and fundamentals stocks screener (44 results) so your watchlist leans on financial strength when conditions get tougher.
• Hunt for potential upside by scanning the 51 high quality undervalued stocks and see which stocks currently trade below their assessed fundamentals.
• Build a watchlist of potential future standouts using the screener containing 23 high quality undiscovered gems before the wider market starts paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.